Anson Funds Management LP Has $9.71 Million Stock Position in SELLAS Life Sciences Group, Inc. $SLS

Anson Funds Management LP boosted its stake in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 2,093.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,032,938 shares of the company’s stock after acquiring an additional 5,757,938 shares during the quarter. SELLAS Life Sciences Group makes up approximately 0.8% of Anson Funds Management LP’s holdings, making the stock its 20th biggest holding. Anson Funds Management LP’s holdings in SELLAS Life Sciences Group were worth $9,713,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its stake in shares of SELLAS Life Sciences Group by 89.2% in the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after acquiring an additional 9,299 shares during the last quarter. Opus Capital Group LLC grew its stake in shares of SELLAS Life Sciences Group by 4.2% during the third quarter. Opus Capital Group LLC now owns 250,000 shares of the company’s stock valued at $403,000 after purchasing an additional 10,000 shares during the last quarter. Equitable Holdings Inc. increased its holdings in shares of SELLAS Life Sciences Group by 58.6% in the third quarter. Equitable Holdings Inc. now owns 27,060 shares of the company’s stock valued at $44,000 after purchasing an additional 10,000 shares in the last quarter. Axxcess Wealth Management LLC acquired a new stake in shares of SELLAS Life Sciences Group in the third quarter valued at approximately $26,000. Finally, ProShare Advisors LLC bought a new position in SELLAS Life Sciences Group in the 2nd quarter worth approximately $43,000. Institutional investors and hedge funds own 17.38% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, SELLAS Life Sciences Group presently has an average rating of “Hold” and a consensus target price of $7.00.

SELLAS Life Sciences Group Stock Up 6.8%

NASDAQ:SLS opened at $5.37 on Friday. SELLAS Life Sciences Group, Inc. has a 12-month low of $0.95 and a 12-month high of $6.14. The stock’s fifty day simple moving average is $4.35 and its 200-day simple moving average is $2.79. The firm has a market capitalization of $764.90 million, a P/E ratio of -19.18 and a beta of 2.18.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.